ArticleFrontiers in oncology2025
A study on the clinical value of prophylactic contralateral central lymph node dissection in patients with cT1-T2N1b unilateral papillary thyroid cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: Lateral lymph node metastasis (cN1b) is a major factor affecting the prognosis and recurrence of papillary thyroid cancer (PTC). Currently, there is some controversy regarding whether to dissect the contralateral central lymph nodes in patients with cT1-T2N1b unilateral PTC. The purpose of this study was to investigate the risk factors for contralateral central lymph node metastasis (CCLNM) and to summarize the significance of prophylactic contralateral central lymph node dissection (CCLND), to provide reference information for clinical intervention. Methods: The data of 99 patients with cT1-T2N1b unilateral PTC from August 2021 to October 2024 were retrospectively analyzed. Multifactorial analysis was performed using logistic regression to analyze the risk factors for CCLNM in patients with cT1-T2N1b unilateral PTC. The analysis of the CCLNM rate and metastasis mode summarized the clinical significance of prophylactic CCLND. Results: CCLNM occurred in 55 cases (55/99,55.6%), and the total number of lymph nodes cleared from the contralateral central lymph node was 6.1 ± 4.9, of which the number of metastatic lymph nodes was 1.5 ± 1.9; There was no statistically significant difference between the CCLNM and non-metastasis groups in terms of the rate of lymph node metastasis in the ipsilateral lateral cervical region (zones II, III, IV and V) and the ipsilateral central zone ( Conclusion: The occurrence of CCLNM in cT1-T2N1b unilateral PTC is related to several factors. Lymph node dissection can help reduce the risk of recurrence and reoperation due to CCLNM; therefore CCLND cannot be ignored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.